Results 161 to 170 of about 7,686 (201)
Some of the next articles are maybe not open access.
Evolocumab: First Global Approval
Drugs, 2015Evolocumab (Repatha™) is a fully human monoclonal antibody developed by Amgen that has been approved as a treatment for hypercholesterolaemia in the EU, and is awaiting approval in the USA and Japan. It specifically binds proprotein convertase subtilisin/kexin type 9 (PCSK9)-a negative regulator of low-density lipoprotein (LDL)-receptors-thereby ...
openaire +2 more sources
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +2 more sources
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +2 more sources
Myocardial Infarction and Evolocumab
JAMA Cardiology, 2021Harvey D, White +2 more
openaire +4 more sources
Evolocumab: A Review in Hyperlipidemia
American Journal of Cardiovascular Drugs, 2015Evolocumab (Repatha(®)) is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg every 2 weeks or 420 mg once monthly. Across 12-week phase III trials in patients with primary hypercholesterolemia or mixed dyslipidemia, evolocumab was more effective than placebo ...
openaire +2 more sources
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
Circulation, 2022Michelle L O'donoghue +2 more
exaly